BNP PARIBAS ASSET MANAGEMENT Holding S.A. Boosts Stock Position in Biogen Inc. $BIIB

BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its position in Biogen Inc. (NASDAQ:BIIB) by 20.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 196,903 shares of the biotechnology company’s stock after purchasing an additional 33,273 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. owned approximately 0.13% of Biogen worth $27,582,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of BIIB. CVA Family Office LLC increased its holdings in Biogen by 18.1% in the 3rd quarter. CVA Family Office LLC now owns 464 shares of the biotechnology company’s stock worth $65,000 after buying an additional 71 shares during the period. TD Private Client Wealth LLC lifted its stake in Biogen by 22.5% during the 3rd quarter. TD Private Client Wealth LLC now owns 414 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 76 shares during the period. CX Institutional boosted its holdings in shares of Biogen by 6.1% in the 3rd quarter. CX Institutional now owns 1,453 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 83 shares during the last quarter. Rothschild Investment LLC boosted its holdings in shares of Biogen by 64.7% in the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 88 shares during the last quarter. Finally, True Wealth Design LLC increased its stake in shares of Biogen by 62.9% in the third quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 90 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Insider Activity

In related news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares in the company, valued at $1,607,232.69. This represents a 24.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.18% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on BIIB. Mizuho boosted their target price on shares of Biogen from $207.00 to $236.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. UBS Group began coverage on Biogen in a research note on Tuesday, January 6th. They set a “neutral” rating and a $185.00 price objective for the company. Tudor Pickering set a $201.00 price objective on Biogen in a report on Monday, February 9th. HC Wainwright upped their target price on Biogen from $194.00 to $228.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Finally, Robert W. Baird reduced their price target on Biogen from $255.00 to $250.00 in a research report on Friday, October 31st. Twelve research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $205.04.

Biogen Stock Down 1.1%

Shares of BIIB opened at $192.08 on Friday. The firm has a market cap of $28.19 billion, a P/E ratio of 21.80, a PEG ratio of 1.54 and a beta of 0.16. Biogen Inc. has a 12 month low of $110.04 and a 12 month high of $202.41. The stock’s 50 day moving average is $179.66 and its two-hundred day moving average is $160.68. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last announced its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same period in the prior year, the company posted $3.44 EPS. The business’s quarterly revenue was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Analysts predict that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.